Zobrazeno 1 - 10
of 110
pro vyhledávání: '"Joseph P. Balthasar"'
Publikováno v:
Cancer Biology & Medicine, Vol 18, Iss 3, Pp 649-664 (2021)
Despite the significant resources dedicated to the development of monoclonal antibody (mAb) therapies for solid tumors, the clinical success, thus far, has been modest. Limited efficacy of mAb in solid tumors likely relates to unique aspects of tumor
Externí odkaz:
https://doaj.org/article/2129f05e18514c9faccbb101a265fdbb
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Our group has developed and experimentally validated a strategy to increase antibody penetration in solid tumors through transient inhibition of antibody-antigen binding. In prior work, we demonstrated that 1HE, an anti-trastuzumab single domain anti
Externí odkaz:
https://doaj.org/article/cc63e946d6224bcfbf2533c43a6dc300
Publikováno v:
Cancer Biology & Medicine, Vol 11, Iss 1, Pp 20-33 (2014)
Since the approval of rituximab in 1997, monoclonal antibodies (mAbs) have become an increasingly important component of therapeutic regimens in oncology. The success of mAbs as a therapeutic class is a result of great strides that have been made in
Externí odkaz:
https://doaj.org/article/0ae2976e2f0e47e9b89952ceb2052405
Autor:
Tommy Li, Joseph P. Balthasar
Publikováno v:
Biomolecules, Vol 8, Iss 4, p 115 (2018)
Quantitative real-time PCR and Western blot methods were developed to assess neonatal Fc-receptor (FcRn) mRNA and protein expression in human FcRn transgenic mice, Swiss Webster mice, and in select human tissues. Additionally, FcRn turnover was evalu
Externí odkaz:
https://doaj.org/article/22011c8ba0a04f98a2a08e43f61eaf7d
Autor:
Shun Xin Wang-Lin, Joseph P. Balthasar
Publikováno v:
Antibodies, Vol 7, Iss 1, p 5 (2018)
Antibiotic-resistant bacterial pathogens are increasingly implicated in hospital- and community-acquired infections. Recent advances in monoclonal antibody (mAb) production and engineering have led to renewed interest in the development of antibody-b
Externí odkaz:
https://doaj.org/article/f817213ea44c472d9cbdd995c0e53e32
Publikováno v:
Molecular Cancer Therapeutics. 22:459-470
Monomethyl auristatin E (MMAE) is a potent tubulin inhibitor that is used as the payload for four FDA-approved antibody–drug conjugates (ADC). Deconjugated MMAE readily diffuses into untargeted cells, resulting in off-target toxicity. Here, we repo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ac7af4335a00b76ef396e3f4a7f067cf
https://doi.org/10.1158/1535-7163.mct-22-0440
https://doi.org/10.1158/1535-7163.mct-22-0440
Publikováno v:
Mol Cancer Ther
We have recently shown that coadministration of mAbs with anti-idiotypic distribution enhancers (AIDE) that inhibit mAb binding to tumor antigens enabled increased intratumoral mAb distribution and increased efficacy of an antibody–drug conjugate (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b168ec2925db48a63be2314295291f87
https://doi.org/10.1158/1535-7163.mct-22-0192
https://doi.org/10.1158/1535-7163.mct-22-0192
Autor:
Joseph P. Balthasar
Publikováno v:
The AAPS Journal. 25
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ba8c4277ea82f739bd6d33cc6a53424b
https://doi.org/10.1208/s12248-023-00816-3
https://doi.org/10.1208/s12248-023-00816-3
Supplementary Figure 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3aca9b27acf67711605a4a7f8f418e9f
https://doi.org/10.1158/1535-7163.22552176.v1
https://doi.org/10.1158/1535-7163.22552176.v1
Supplementary Table 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03a3eb87165b84db53f87e2638195791
https://doi.org/10.1158/1535-7163.22552164
https://doi.org/10.1158/1535-7163.22552164